modelCefepimeAndBetaLactamase
Extends from Pharmacolibrary.Drugs.ATC.J.J01DE51.
Information
| name: | CefepimeAndBetaLactamaseInhibitor | |
| ATC code: | J01DE51 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 2000 | mg |
| volume of distribution: | 13 | L |
| clearance: | 4.8 | L/h |
| other parameters in model implementation | ||
Cefepime is a fourth-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria. It is often combined with a beta-lactamase inhibitor (such as tazobactam or zidebactam) to extend its activity against beta-lactamase-producing bacteria. These combinations are typically used in treatment of complicated urinary tract infections, hospital-acquired pneumonia, and other serious infections. As of now, cefepime-beta-lactamase inhibitor combinations (ATC J01DE51) are not widely approved as co-formulations, and clinical use may be limited to investigational or compassionate settings.
Pharmacokinetics
No published pharmacokinetic data available specifically for cefepime and a beta-lactamase inhibitor combination. The following parameters are estimated based on known pharmacokinetics of cefepime (adult, intravenous administration, normal renal function) and commonly used beta-lactamase inhibitors.
References
Zhanel, GG, et al., & Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 79(3) 271–289. DOI:10.1007/s40265-019-1055-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30712199
Das, S, et al., & Hope, W (2020). Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. Antimicrobial agents and chemotherapy 65(1) –. DOI:10.1128/AAC.01468-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33077666
Chen, M, et al., & Fahim, G (2019). Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 76(18) 1383–1394. DOI:10.1093/ajhp/zxz154 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31505562
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)